Article
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Neuro-oncology - 14 Mar 2023
Sigaud Romain, Rösch Lisa, Gatzweiler Charlotte, Benzel Julia, von Soosten Laura, Peterziel Heike, Selt Florian, Najafi Sara, Ayhan Simay, Gerloff Xenia F, Hofmann Nina, Büdenbender Isabel, Schmitt Lukas, Foerster Kathrin I, Burhenne Jürgen, Haefeli Walter E, Korshunov Andrey, Sahm Felix, van Tilburg Cornelis M, Jones David T W, Pfister Stefan M, Knoerzer Deborah, Kreider Brent L, Sauter Max, Pajtler Kristian W, Zuckermann Marc, Oehme Ina, Witt Olaf, Milde Till
Abstract excerpt
BACKGROUND: Pediatric low-grade gliomas (pLGG) are the most common pediatric central nervous system tumors, with driving alterations typically occurring in the MAPK pathway. The ERK1/2 inhibitor ulixertinib (BVD-523) has shown promising responses in adult patients with mitogen-activated protein kinase (MAPK)-driven solid tumors. METHODS: We investigated the antitumoral activity of ulixertinib monotherapy as well...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.